You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: R

    DESCRIPTION Based on the prevailing evidence we believe that a highly effective vaccine for HIV prophylaxis must induce long lasting broadly cross reactive antibody responses to envelope that exhibit antiviral activity as well as multi antigen polyfunctional CD and CD T cell responses that produce antiviral chemokines and cytokines and are possibly biased towards an effector memory phenot ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Staphylococcus aureus is a Gram positive human pathogen that causes a wide range of infections from skin and soft tissue infections SSTI to life threatening sepsis and pneumonia The pathogenicity of S aureus is dependent on numerous virulence factors including cell surface proteins and polysaccharides as well as secreted toxins An important group of thes ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid STEMI Fibrinolysis for Underserved Populations

    SBC: Pulse Therapeutics, Inc.            Topic: NIMHD

    DESCRIPTION provided by applicant Coronary heart disease CHD accounts for every of deaths in the United States US with acute incidences estimated at M annually Of these up to are classified as ST elevation myocardial infarction STEMI in which a clot blocks a coronary artery leading to a change in the ECG ST wave Because the heart muscle rapidly dies time to re ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Automating mosquito microdissection for a malaria PfSPZ vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION Malaria causes andgt million clinical cases and million deaths annually is responsible for andgt loss of GDP in Africa and is a serious concern for travelers and military personnel A highly effective vaccine is desperately needed and radiation attenuated Plasmodium falciparum Pf sporozoites SPZ and non attenuated PfSPZ with chloroquine chemoprophylaxis ChemoProphylax ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. AAAPT Technology for Improving Chemotherapy

    SBC: SCI-ENGI-MEDCO SOLUTIONS, INC            Topic: NCI

    DESCRIPTION provided by applicant Dysregulation of apoptosis pathways and loss of Human Beta Defensin hBD are the common tactics adapted by cancer cells to circumvent the effects of chemotherapy Consequently high dose of chemotherapy is required to obtain a clinically relevant therapeutic index which in turn compromises safety and develops resistance to therapy The problem is acute p ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Anti-virulence FimH inhibitors for the treatment and prevention of UTIs

    SBC: FIMBRION THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION provided by applicant Over million women suffer from urinary tract infections UTI annually in the U S and approximately of these patients suffer from multiple recurrences UTI is unique in its high prevalence of chronic recurrent infections which has caused a tremendous need for long term conventional prophylactic therapy This is leading to increased antimicrobial res ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD

    SBC: Asclepix Therapeutics, Inc.            Topic: N

    DESCRIPTION provided by applicant Long term anti angiogenic activity of intravitreal ellipsoid particles for NVAMD Niranjan B Pandey Ph D PI Aleksander S Popel Ph D Co I Jordan J Green Ph D Co I Peter A Campochiaro M D Co I of subaward Project Summary Current therapies for wet age related macular degeneration AMD target vascular endothelial growth factors VEGFA and pla ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Experimental Design Software for Translational Gastrointestinal Microbiome Studie

    SBC: WILLIAM D SHANNON CONSULTING LLC            Topic: 300

    DESCRIPTION provided by applicant Design of experiments and test of hypotheses need to be available to research teams to develop and validate taxonomic metagenomic biomarkers in gastrointestinal tract GIT diseases The translational research team needs to design an experiment to test a hypothesis e g microbiota in Crohnandapos s disease is different than in normal controls calculat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government